Loading...
•
Dec 31, 2023
Harmony Biosciences Q4 2023 Earnings Report
Harmony Biosciences reported net revenue growth for Q4 and full year 2023, driven by strong WAKIX sales and clinical development advancements.
Key Takeaways
Harmony Biosciences reported a strong Q4 2023, with net product revenue of $168.4 million, a 31% increase compared to the same period in 2022. GAAP net income was $26.6 million, or $0.45 per diluted share, while Non-GAAP adjusted net income was $42.8 million, or $0.73 per diluted share. The company is projecting net product revenue between $700 and $720 million for 2024.
Net product revenue for the quarter was $168.4 million, a 31% increase compared to 2022.
GAAP net income for the quarter was $26.6 million, or $0.45 per diluted share.
Non-GAAP adjusted net income was $42.8 million, or $0.73 per diluted share.
FDA granted priority review for WAKIX in pediatric narcolepsy with a PDUFA date of June 21, 2024.
Revenue by Segment
Forward Guidance
Harmony Biosciences expects full year 2024 net product revenue of $700 million to $720 million.
Positive Outlook
- Full year 2024 net product revenue expected to be between $700 million and $720 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...